NuWays keeps Buy on Readcrest Capital, sets price target at EUR 2.80
Bitget2026/10/05 07:01NuWays reiterated a BUY rating on Readcrest Capital, keeping its 12-month target price at EUR 2.80. H1 sales were EUR 65.3 million, up 1.6% year over year, driven by UK home care pricing gains and bolt-on acquisitions. Group EBITDA fell to EUR 3.4 million from EUR 5.5 million, pressured by holding costs and consolidation expenses. Net debt dropped to EUR 123.5 million from EUR 180.1 million following a care home portfolio disposal and debt repayment. Guidance stayed unchanged, with management targeting EBITDA of at least EUR 22 million, including at least EUR 14 million from creditor waivers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Readcrest Capital AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26960) on October 05, 2026, and is solely responsible for the information contained therein.
- NuWays reiterated a BUY rating on Readcrest Capital, keeping its 12-month target price at EUR 2.80.
- H1 sales were EUR 65.3 million, up 1.6% year over year, driven by UK home care pricing gains and bolt-on acquisitions.
- Group EBITDA fell to EUR 3.4 million from EUR 5.5 million, pressured by holding costs and consolidation expenses.
- Net debt dropped to EUR 123.5 million from EUR 180.1 million following a care home portfolio disposal and debt repayment.
- Guidance stayed unchanged, with management targeting EBITDA of at least EUR 22 million, including at least EUR 14 million from creditor waivers.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
This AI Stock Exploded 600% in a Year, Beating Nvidia and Micron
House Finance panel chair says regulator actions on crypto ‘fall short’ of CLARITY bill

Vietnam: Strong GDP but rising inflation risks – Commerzbank
Incordex appoints Chen Wang to board of directors
Incordex appointed Chen Wang to its board effective Sept. 29, 2026. Wang founded his own brand. He has served as founder and board chairman of Yunnan Jinshengchang Technology and Trade since Oct. 2024. He previously led global pharmaceutical education operations at Meixin E-commerce. He later ran education operations at Zhuyuan Grop. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incordex Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-006080), on October 07, 2026, and is solely responsible for the information contained therein.